EMA finds lack of evidence on pancreatic risks with GLP-1s

Current evidence does not show that glucagon-like peptide-1 agonists increase the risk of pancreatitis and pancreatic-duct metaplasia in patients with type 2 diabetes, the European Medicines Agency's Committee for Medicinal Products for Human Use indicated. "However, the number of events is too small to draw final conclusions. Due to their mechanism of action, some uncertainties remain in respect to the long-term effect of these medicines on the pancreas, and more data collection efforts are under way," the agency stated.

View Full Article in:

Healio · New York Times (tiered subscription model), The · PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA